Insight Molecular Diagnostics Inc. reported revenues of $0.26 million in Q3 2025, derived from laboratory services performed at its Nashville clinical laboratory. The company remains pre-revenue in relation to kitted product sales, with no kitted product revenue recognized in the quarter. Gross profit was $0.14 million, representing a 53.5% gross margin. Research and development expenses rose 18% sequentially to $3.9 million, while sales and marketing expenses declined 5% to $1.4 million. General and administrative expenses decreased 4% to $2.5 million. The company reported a net loss of $10.9 million, or ($0.34) per share. Cash, cash equivalents, and restricted cash totaled $20.2 million at quarter end. Outgoing cash flow from operations was $4.6 million, with capital expenditures of $1.1 million. The company continues to invest in FDA-compliant product development and anticipates increased expenses in Q4 2025 related to its FDA program.